SG11202011097YA - Bioreactor for rna in vitro transcription - Google Patents
Bioreactor for rna in vitro transcriptionInfo
- Publication number
- SG11202011097YA SG11202011097YA SG11202011097YA SG11202011097YA SG11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA SG 11202011097Y A SG11202011097Y A SG 11202011097YA
- Authority
- SG
- Singapore
- Prior art keywords
- bioreactor
- rna
- vitro transcription
- transcription
- vitro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/45—Magnetic mixers; Mixers with magnetically driven stirrers
- B01F33/451—Magnetic mixers; Mixers with magnetically driven stirrers wherein the mixture is directly exposed to an electromagnetic field without use of a stirrer, e.g. for material comprising ferromagnetic particles or for molten metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/45—Magnetic mixers; Mixers with magnetically driven stirrers
- B01F33/452—Magnetic mixers; Mixers with magnetically driven stirrers using independent floating stirring elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/50—Mixing receptacles
- B01F35/53—Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components
- B01F35/531—Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components with baffles, plates or bars on the wall or the bottom
- B01F35/5312—Mixing receptacles characterised by the configuration of the interior, e.g. baffles for facilitating the mixing of components with baffles, plates or bars on the wall or the bottom with vertical baffles mounted on the walls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/90—Heating or cooling systems
- B01F35/92—Heating or cooling systems for heating the outside of the receptacle, e.g. heated jackets or burners
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/18—Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
- C12M27/02—Stirrer or mobile mixing elements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/90—Heating or cooling systems
- B01F2035/98—Cooling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/90—Heating or cooling systems
- B01F2035/99—Heating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
- B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/10—Nucleotidyl transfering
- C12Q2521/119—RNA polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/143—Magnetism, e.g. magnetic label
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Sustainable Development (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Computer Hardware Design (AREA)
- Mycology (AREA)
- Botany (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018067504 | 2018-06-28 | ||
| PCT/EP2019/067323 WO2020002598A1 (en) | 2018-06-28 | 2019-06-28 | Bioreactor for rna in vitro transcription |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011097YA true SG11202011097YA (en) | 2020-12-30 |
Family
ID=62837899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011097YA SG11202011097YA (en) | 2018-06-28 | 2019-06-28 | Bioreactor for rna in vitro transcription |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12371646B2 (en) |
| EP (2) | EP3814495B1 (en) |
| JP (1) | JP7352581B2 (en) |
| KR (1) | KR20210027368A (en) |
| CN (1) | CN112334579B (en) |
| AU (1) | AU2019293714C1 (en) |
| BR (1) | BR112020025601A8 (en) |
| CA (1) | CA3102135A1 (en) |
| IL (1) | IL279759B2 (en) |
| MX (1) | MX2020013148A (en) |
| RU (1) | RU2765877C1 (en) |
| SG (1) | SG11202011097YA (en) |
| WO (1) | WO2020002598A1 (en) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| MX362981B (en) | 2012-03-27 | 2019-02-28 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression. |
| CN105517569A (en) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | Rabies vaccine |
| SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
| CN105473157A (en) | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | Combination vaccine |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| ES2754239T3 (en) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combination of vaccination and OX40 agonists |
| DE202015009961U1 (en) | 2014-12-12 | 2022-01-25 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
| WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
| ES2960429T3 (en) | 2015-05-29 | 2024-03-04 | Curevac Mfg Gmbh | Method for producing and purifying RNA, comprising at least one tangential flow filtration step |
| EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| AU2016375021B2 (en) | 2015-12-22 | 2022-02-03 | CureVac SE | Method for producing RNA molecule compositions |
| US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| EP4477662A3 (en) | 2016-05-04 | 2025-03-19 | CureVac SE | Nucleic acid molecules and uses thereof |
| US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
| WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
| EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
| US12297489B2 (en) | 2017-05-17 | 2025-05-13 | CureVac Manufacturing GmbH | Method for determining at least one quality parameter of an RNA sample |
| WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
| RU2020117848A (en) | 2017-11-08 | 2021-12-08 | Куревак Аг | PHK SEQUENCE ADAPTATION |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| WO2019202035A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| SG11202011097YA (en) | 2018-06-28 | 2020-12-30 | Curevac Ag | Bioreactor for rna in vitro transcription |
| US11421226B2 (en) * | 2018-10-17 | 2022-08-23 | Ramot At Tel-Aviv University Ltd. | Programmable artificial cell |
| TW202039534A (en) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | Kras variant mrna molecules |
| SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| AU2021216658A1 (en) | 2020-02-04 | 2022-06-23 | CureVac SE | Coronavirus vaccine |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| EP4132478A1 (en) | 2020-04-09 | 2023-02-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| CN115667509A (en) * | 2020-05-01 | 2023-01-31 | 螺旋纳米技术公司 | Compositions and methods for RNA synthesis |
| EP4150105A1 (en) * | 2020-05-12 | 2023-03-22 | Makatsoris, Charalampos | A method and modular apparatus for the synthesis of rna-based therapeutics |
| GB2597436B (en) * | 2020-05-12 | 2025-03-26 | Makatsoris Charalampos | A method and apparatus for RNA synthesis |
| BR112022024248A2 (en) | 2020-05-29 | 2023-10-10 | CureVac SE | NUCLEIC ACID-BASED COMBINATION VACCINES |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| US20240246056A1 (en) | 2020-09-01 | 2024-07-25 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| US12458604B2 (en) | 2020-10-14 | 2025-11-04 | The Trustees Of The University Of Pennsylvania | Methods of lipid nanoparticle manufacture and compositions derived therefrom |
| GB2617472B (en) * | 2020-10-23 | 2025-08-06 | Linearx Inc | Compositions and methods for RNA synthesis |
| WO2022112498A1 (en) | 2020-11-27 | 2022-06-02 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| US20240150719A1 (en) * | 2021-02-22 | 2024-05-09 | The Board Of Regents Of The University Of Texas System | Magnetic shear bioreactor apparatus and methods |
| MX2023011400A (en) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Immunogenic compositions. |
| EP4351777A4 (en) * | 2021-06-07 | 2025-04-16 | The University of Massachusetts | Apparatus and method for continuous production of rna |
| BE1030468B1 (en) | 2022-04-20 | 2023-11-21 | Quantoom Biosciences S A | SYSTEM AND METHOD FOR RNA PRODUCTION |
| CN119234155A (en) | 2022-04-15 | 2024-12-31 | 广通生物科学公司 | System and method for producing RNA |
| CN114540444B (en) * | 2022-04-23 | 2022-08-09 | 江苏申基生物科技有限公司 | Capping composition, preparation method thereof and in-vitro transcription reaction system |
| CN115106356B (en) * | 2022-07-06 | 2023-06-06 | 眉山市城投中恒能环保科技有限公司 | Treatment method and treatment system for kitchen waste recovery |
| AU2023353931A1 (en) | 2022-09-26 | 2025-03-20 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4344769B1 (en) * | 2022-09-30 | 2025-03-19 | Technische Universität Clausthal | System for continuous manufacture of biomolecules |
| DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
| CN116180478A (en) * | 2023-02-28 | 2023-05-30 | 江苏理文造纸有限公司 | Utilize straw automation papermaking device |
| CN222476570U (en) | 2023-03-17 | 2025-02-14 | 广通生物科学公司 | System and treatment vessel for treating biochemical products by means of magnetic particles |
| WO2024209418A1 (en) * | 2023-04-07 | 2024-10-10 | BioNTech SE | Heating and cooling jacket for fluid vessels |
| WO2024235451A1 (en) | 2023-05-16 | 2024-11-21 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2025022178A2 (en) * | 2023-07-24 | 2025-01-30 | Apte Zachary Schulz | In-situ mrna vaccine production method and device |
| WO2025040263A1 (en) | 2023-08-24 | 2025-02-27 | CureVac Manufacturing GmbH | Purification process for in vitro amplified dna |
| KR20250047212A (en) * | 2023-09-27 | 2025-04-03 | 포항공과대학교 산학협력단 | Microfluid reaction device and mRNA synthesis method using the same |
| CN119709730A (en) * | 2023-09-28 | 2025-03-28 | 康码(上海)生物科技有限公司 | A DNA microsphere and its preparation method and application |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025144938A1 (en) | 2023-12-26 | 2025-07-03 | Emmune, Inc. | Systems for nucleic acid transfer |
| GB202406294D0 (en) | 2024-05-06 | 2024-06-19 | Thermo Fisher Scientific Baltics Uab | Methods and compositions for producing capped mRNA |
| EP4660288A1 (en) | 2024-06-07 | 2025-12-10 | Sartorius Stedim Biotech GmbH | Bioreactor, bioreactor vessel and closure component for a bioreactor vessel |
| EP4660291A1 (en) | 2024-06-07 | 2025-12-10 | Sartorius Stedim Biotech GmbH | Bioreactor and bioreactor vessel |
| WO2026003316A1 (en) * | 2024-06-28 | 2026-01-02 | BioNTech SE | Method for pcr |
| CN120115054B (en) * | 2025-05-08 | 2025-08-05 | 南京航空航天大学 | A powder mixing method for a lunar base sandwich shell and a sandwich shell structure |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2898565A (en) * | 1954-07-02 | 1959-08-04 | Mc Graw Edison Co | Magnetic core |
| SE460706B (en) * | 1987-12-30 | 1989-11-13 | Stefan Loefgren | OMROERNINGSORGAN |
| US6884357B2 (en) * | 1995-02-21 | 2005-04-26 | Iqbal Waheed Siddiqi | Apparatus and method for processing magnetic particles |
| US6955793B1 (en) * | 1997-06-18 | 2005-10-18 | Arencibia Jr Jose P | Temperature controlled reaction vessel |
| US6361749B1 (en) * | 1998-08-18 | 2002-03-26 | Immunivest Corporation | Apparatus and methods for magnetic separation |
| WO2000062034A2 (en) * | 1999-04-09 | 2000-10-19 | Shot, Inc. | Multistage electromagnetic separator for purifying cells, chemicals and protein structures |
| ES2340499T3 (en) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | TUMOR ANTIGEN ARNM STABILIZED WITH AN INCREASED G / C CONTENT. |
| DE10162480A1 (en) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
| DE10229872A1 (en) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immune stimulation through chemically modified RNA |
| WO2004015062A2 (en) * | 2002-08-12 | 2004-02-19 | New England Biolabs, Inc. | Methods and compositions relating to gene silencing |
| DE10335833A1 (en) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfection of blood cells with mRNA for immune stimulation and gene therapy |
| DE102004042546A1 (en) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Combination therapy for immune stimulation |
| DE102005023170A1 (en) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimized formulation for mRNA |
| FI20051248L (en) | 2005-12-02 | 2007-06-03 | Bio Nobile Oy | Enrichment unit and enrichment method for biological components |
| DE102006035618A1 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nucleic acid of the formula (I): GlXmGn, in particular as immunostimulating adjuvant |
| DE102006061015A1 (en) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Process for the purification of RNA on a preparative scale by HPLC |
| DE102007001370A1 (en) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
| GB0724404D0 (en) | 2007-05-29 | 2008-01-30 | Invitrogen Dynal As | A sample vessel retaining portion |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| KR101483715B1 (en) | 2008-01-31 | 2015-01-19 | 큐어백 게엠바하 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS/ADJUVANTS |
| EP2306959A2 (en) * | 2008-07-11 | 2011-04-13 | The General Hospital Corporation | Magnetic apparatus for blood separation |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| US9157891B2 (en) * | 2008-10-16 | 2015-10-13 | Koninklijke Philips N.V. | Biosensor with quadrupole magnetic actuation system |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| GB2481425A (en) * | 2010-06-23 | 2011-12-28 | Iti Scotland Ltd | Method and device for assembling polynucleic acid sequences |
| ES2558106T3 (en) | 2010-07-30 | 2016-02-02 | Curevac Ag | Formation of nucleic acid complexes with disulfide-cross-linked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| KR101870311B1 (en) * | 2012-03-09 | 2018-06-25 | (주)바이오니아 | Compositions for hot start reverse transcription reaction or hot start reverse transcription polymerase chain reaction |
| MX362981B (en) | 2012-03-27 | 2019-02-28 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression. |
| CA2866955A1 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
| ES2660129T3 (en) | 2012-03-27 | 2018-03-20 | Curevac Ag | Artificial nucleic acid molecules comprising a 5'UTR-TOP |
| GB201208547D0 (en) * | 2012-05-15 | 2012-06-27 | Life Technologies As | Sample holder |
| EP3498267A1 (en) | 2012-05-25 | 2019-06-19 | CureVac AG | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| MX385338B (en) | 2013-02-22 | 2025-03-18 | CureVac SE | Combination of vaccination and inhibition of the pd-1 pathway |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| PT2970948T (en) * | 2013-03-15 | 2019-03-20 | Glaxosmithkline Biologicals Sa | RNA Purification Methods |
| SG11201510748PA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
| CN105473157A (en) | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | Combination vaccine |
| CN105517569A (en) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | Rabies vaccine |
| SG11201510746WA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
| AU2014310930A1 (en) | 2013-08-21 | 2016-01-21 | Curevac Ag | Composition and vaccine for treating prostate cancer |
| CN105451779A (en) | 2013-08-21 | 2016-03-30 | 库瑞瓦格股份公司 | Method for increasing expression of RNA-encoded proteins |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
| KR102399799B1 (en) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | Artificial nucleic acid molecules |
| ES2754239T3 (en) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combination of vaccination and OX40 agonists |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| MX382298B (en) * | 2014-06-10 | 2025-03-12 | Curevac Mfg Gmbh | METHODS AND MEANS FOR INCREASING RNA PRODUCTION. |
| ES2711852T3 (en) * | 2014-08-12 | 2019-05-07 | Abb Schweiz Ag | Magnet that presents regions of different magnetic properties and procedure to form said magnet |
| WO2016062788A1 (en) * | 2014-10-24 | 2016-04-28 | Ait Austrian Institute Of Technology Gmbh | Microfluidic chip for biological analysis |
| DE202015009961U1 (en) | 2014-12-12 | 2022-01-25 | Curevac Ag | Artificial nucleic acid molecules for improved protein expression |
| CA2962849A1 (en) | 2014-12-16 | 2016-06-23 | Curevac Ag | Ebolavirus and marburgvirus vaccines |
| CA2966092A1 (en) | 2014-12-30 | 2016-07-07 | Curevac Ag | Artificial nucleic acid molecules |
| EP4353257A3 (en) | 2015-04-13 | 2024-08-07 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| CN107567497A (en) | 2015-04-17 | 2018-01-09 | 库瑞瓦格股份公司 | Lyophilization of RNA |
| US10293058B2 (en) | 2015-04-22 | 2019-05-21 | Curevac Ag | RNA containing composition for treatment of tumor diseases |
| SG11201708681SA (en) | 2015-04-30 | 2017-11-29 | Curevac Ag | Method for in vitro transcription using an immobilized restriction enzyme |
| EP3289101B1 (en) | 2015-04-30 | 2021-06-23 | CureVac AG | Immobilized poly(n)polymerase |
| WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
| KR20180004820A (en) | 2015-05-15 | 2018-01-12 | 큐어백 아게 | A novel prime-boost therapy comprising administration of at least one mRNA construct |
| EP3916091A3 (en) | 2015-05-20 | 2022-03-30 | CureVac AG | Dry powder composition comprising long-chain rna |
| WO2016184576A2 (en) | 2015-05-20 | 2016-11-24 | Curevac Ag | Dry powder composition comprising long-chain rna |
| ES2960429T3 (en) | 2015-05-29 | 2024-03-04 | Curevac Mfg Gmbh | Method for producing and purifying RNA, comprising at least one tangential flow filtration step |
| EP3303575B1 (en) | 2015-05-29 | 2022-03-16 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| EP4239080A3 (en) | 2015-07-01 | 2023-11-01 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
| US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
| WO2017021546A1 (en) | 2015-08-05 | 2017-02-09 | Curevac Ag | Epidermal mrna vaccine |
| WO2017025120A1 (en) | 2015-08-07 | 2017-02-16 | Curevac Ag | Process for the in vivo production of rna in a host cell |
| EP3825407A1 (en) | 2015-08-10 | 2021-05-26 | CureVac Real Estate GmbH | Method of increasing the replication of a circular dna molecule |
| AU2016316439B2 (en) | 2015-08-28 | 2022-02-24 | CureVac SE | Artificial nucleic acid molecules |
| LT4104687T (en) | 2015-09-21 | 2024-02-26 | Trilink Biotechnologies, Llc | Compositions and methods for synthesizing 5 -capped rnas |
| EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| US20180312545A1 (en) | 2015-11-09 | 2018-11-01 | Curevac Ag | Optimized nucleic acid molecules |
| EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| JP2017085951A (en) | 2015-11-09 | 2017-05-25 | 株式会社リコー | Jig, processing apparatus, processing method, and cDNA synthesis method |
| WO2017090134A1 (en) | 2015-11-25 | 2017-06-01 | 神栄テクノロジー株式会社 | Particle sensor |
| WO2017108087A1 (en) | 2015-12-21 | 2017-06-29 | Curevac Ag | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
| AU2016375021B2 (en) | 2015-12-22 | 2022-02-03 | CureVac SE | Method for producing RNA molecule compositions |
| WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| WO2017137095A1 (en) | 2016-02-12 | 2017-08-17 | Curevac Ag | Method for analyzing rna |
| EP3417069A1 (en) | 2016-02-15 | 2018-12-26 | CureVac AG | Method for analyzing by-products of rna in vitro transcription |
| US11723967B2 (en) | 2016-02-17 | 2023-08-15 | CureVac SE | Zika virus vaccine |
| EP3423595A1 (en) | 2016-03-03 | 2019-01-09 | CureVac AG | Rna analysis by total hydrolysis |
| EP3433361A1 (en) | 2016-03-24 | 2019-01-30 | CureVac AG | Immobilized inorganic pyrophosphatase (ppase) |
| US20190343942A1 (en) | 2016-04-22 | 2019-11-14 | Curevac Ag | Rna encoding a tumor antigen |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
| EP4477662A3 (en) | 2016-05-04 | 2025-03-19 | CureVac SE | Nucleic acid molecules and uses thereof |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| EP4233898A3 (en) | 2016-05-04 | 2023-11-01 | CureVac SE | Influenza mrna vaccines |
| EP3464619A1 (en) | 2016-05-25 | 2019-04-10 | CureVac AG | Novel biomarkers |
| US11478552B2 (en) | 2016-06-09 | 2022-10-25 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| EP3468609A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Cationic carriers for nucleic acid delivery |
| WO2017212008A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| US20190336611A1 (en) | 2016-06-09 | 2019-11-07 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
| BR112019000598A2 (en) | 2016-08-19 | 2019-07-02 | Curevac Ag | rna for cancer therapy |
| WO2018041921A1 (en) | 2016-08-31 | 2018-03-08 | Curevac Ag | Mixing device for the production of a liquid nucleic acid composition |
| JP2018057333A (en) | 2016-10-06 | 2018-04-12 | 株式会社リコー | TREATMENT KIT, TREATMENT METHOD, cDNA SYNTHESIS METHOD AND TREATMENT DEVICE |
| WO2018075827A1 (en) | 2016-10-19 | 2018-04-26 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
| KR20190093816A (en) | 2016-10-26 | 2019-08-26 | 큐어백 아게 | Lipid nanoparticle mRNA vaccine |
| WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
| US11464836B2 (en) | 2016-12-08 | 2022-10-11 | Curevac Ag | RNA for treatment or prophylaxis of a liver disease |
| WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
| US11524066B2 (en) | 2016-12-23 | 2022-12-13 | CureVac SE | Henipavirus vaccine |
| US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
| WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
| EP3595715A1 (en) | 2017-03-17 | 2020-01-22 | CureVac AG | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| CN106916743B (en) | 2017-03-19 | 2019-02-12 | 北京化工大学 | Integrated nucleic acid extraction and amplification detection system |
| EP3601576A1 (en) | 2017-03-24 | 2020-02-05 | CureVac AG | Nucleic acids encoding crispr-associated proteins and uses thereof |
| US12297489B2 (en) | 2017-05-17 | 2025-05-13 | CureVac Manufacturing GmbH | Method for determining at least one quality parameter of an RNA sample |
| EP3424524B1 (en) | 2017-07-04 | 2024-12-11 | CureVac SE | Cancer rna-vaccine |
| WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
| MX2020003995A (en) | 2017-10-19 | 2020-07-22 | Curevac Ag | NEW ARTIFICIAL NUCLEIC ACID MOLECULES. |
| RU2020117848A (en) | 2017-11-08 | 2021-12-08 | Куревак Аг | PHK SEQUENCE ADAPTATION |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| SG11202005760PA (en) | 2017-12-21 | 2020-07-29 | Curevac Ag | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
| EP3773702A2 (en) | 2018-04-05 | 2021-02-17 | CureVac AG | Novel yellow fever nucleic acid molecules for vaccination |
| WO2019202035A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| SG11202011097YA (en) | 2018-06-28 | 2020-12-30 | Curevac Ag | Bioreactor for rna in vitro transcription |
| TW202039534A (en) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | Kras variant mrna molecules |
| SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
| US20220040281A1 (en) | 2018-12-21 | 2022-02-10 | Curevac Ag | Rna for malaria vaccines |
| EP4491229A3 (en) | 2019-02-08 | 2025-05-14 | CureVac SE | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| KR20220047319A (en) | 2019-08-14 | 2022-04-15 | 큐어백 아게 | RNA Combinations and Compositions with Reduced Immunostimulatory Properties |
| EP4076647A1 (en) | 2019-12-20 | 2022-10-26 | CureVac AG | Lipid nanoparticles for delivery of nucleic acids |
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| BR112022024248A2 (en) | 2020-05-29 | 2023-10-10 | CureVac SE | NUCLEIC ACID-BASED COMBINATION VACCINES |
| EP4165205A1 (en) | 2020-06-15 | 2023-04-19 | CureVac SE | Analysis of nucleic acid mixtures |
-
2019
- 2019-06-28 SG SG11202011097YA patent/SG11202011097YA/en unknown
- 2019-06-28 KR KR1020217001173A patent/KR20210027368A/en not_active Abandoned
- 2019-06-28 CN CN201980043390.1A patent/CN112334579B/en active Active
- 2019-06-28 EP EP19733798.3A patent/EP3814495B1/en active Active
- 2019-06-28 AU AU2019293714A patent/AU2019293714C1/en active Active
- 2019-06-28 BR BR112020025601A patent/BR112020025601A8/en not_active IP Right Cessation
- 2019-06-28 WO PCT/EP2019/067323 patent/WO2020002598A1/en not_active Ceased
- 2019-06-28 US US17/254,853 patent/US12371646B2/en active Active
- 2019-06-28 JP JP2020567587A patent/JP7352581B2/en active Active
- 2019-06-28 EP EP23175456.5A patent/EP4273266A3/en not_active Withdrawn
- 2019-06-28 CA CA3102135A patent/CA3102135A1/en active Pending
- 2019-06-28 MX MX2020013148A patent/MX2020013148A/en unknown
- 2019-06-28 RU RU2020141236A patent/RU2765877C1/en active
-
2020
- 2020-12-24 IL IL279759A patent/IL279759B2/en unknown
-
2025
- 2025-06-20 US US19/244,186 patent/US20250313788A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021528051A (en) | 2021-10-21 |
| EP4273266A3 (en) | 2024-03-13 |
| IL279759A (en) | 2021-03-01 |
| US20250313788A1 (en) | 2025-10-09 |
| AU2019293714B2 (en) | 2023-03-30 |
| EP3814495A1 (en) | 2021-05-05 |
| WO2020002598A1 (en) | 2020-01-02 |
| CN112334579A (en) | 2021-02-05 |
| RU2765877C1 (en) | 2022-02-04 |
| BR112020025601A8 (en) | 2022-07-05 |
| IL279759B2 (en) | 2026-02-01 |
| JP7352581B2 (en) | 2023-09-28 |
| US20210261897A1 (en) | 2021-08-26 |
| EP3814495B1 (en) | 2023-06-07 |
| EP3814495C0 (en) | 2023-06-07 |
| CA3102135A1 (en) | 2020-01-02 |
| EP4273266A2 (en) | 2023-11-08 |
| KR20210027368A (en) | 2021-03-10 |
| MX2020013148A (en) | 2021-03-02 |
| US12371646B2 (en) | 2025-07-29 |
| CN112334579B (en) | 2026-01-16 |
| AU2019293714A1 (en) | 2020-11-12 |
| IL279759B1 (en) | 2025-10-01 |
| AU2019293714C1 (en) | 2023-09-21 |
| BR112020025601A2 (en) | 2021-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279759B2 (en) | Bioreactor for rna in vitro transcription | |
| SG11201708681SA (en) | Method for in vitro transcription using an immobilized restriction enzyme | |
| EP3938507A4 (en) | Fed-batch in vitro transcription process | |
| EP3728596A4 (en) | Nucleic acid construct for in vitro and in vivo gene expression | |
| SG11202011539VA (en) | Modified guide rnas for gene editing | |
| EP3504315A4 (en) | Bioreactor | |
| ZA201902420B (en) | Method for amplifying antigen-specific regulatory t cells in vitro | |
| PT3294903T (en) | Method for in vitro diagnosis of dementia with lewy bodies using alphasynuclein gene transcripts | |
| EP3749335A4 (en) | Perfusion enabled bioreactors | |
| GB201913196D0 (en) | Culture method | |
| EP3717631C0 (en) | Cell culture methods | |
| IL314599A (en) | Cell culture methods | |
| EP3164495A4 (en) | Microorganisms for producing 4c-5c compounds with unsaturation and methods related thereto | |
| EP3368537A4 (en) | Process for preparing ibrutinib and its intermediates | |
| GB201909144D0 (en) | Culture medium | |
| IL262125A (en) | Selective bioreactor for microalgae | |
| GB201814532D0 (en) | in vitro dianostic assay methods | |
| PL3630946T3 (en) | Cell culture methods | |
| EP3069591A4 (en) | Bioreactor for in vitro plant culture | |
| EP3389363B8 (en) | A process for in vitro | |
| SG11202111135PA (en) | Cell culture media comprising keto acids | |
| EP3681365A4 (en) | Large-scale bioreactor | |
| PT3841214T (en) | Charcoal-free culture media for legionella | |
| LT3234100T (en) | Bioreactor and fermentation process for producing hydrogen | |
| PL3647404T3 (en) | Bioreactor |